Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13744
Title: Adrenaline: insights into its metabolic roles in hypoglycaemia and diabetes
Austin Authors: Verberne, Anthony JM;Korim, Willian S;Sabetghadam, Azadeh;Llewellyn-Smith, Ida J
Affiliation: University of Melbourne, Clinical Pharmacology and Therapeutics Unit, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia
Cardiovascular Medicine and Human Physiology, Flinders University, Bedford Park, South Australia, Australia
Issue Date: May-2016
metadata.dc.date: 2016-02-20
Publication information: British Journal of Pharmacology 2016; 173(9): 1425-1437
Abstract: Adrenaline is a hormone that has profound actions on the cardiovascular system and is also a mediator of the fight-or-flight response. Adrenaline is now increasingly recognised as an important metabolic hormone that helps mobilise energy stores in the form of glucose and free fatty acids in preparation for physical activity or for recovery from hypoglycaemia. Recovery from hypoglycaemia is termed counter-regulation and involves suppression of endogenous insulin secretion, activation of glucagon secretion from pancreatic α-cells and activation of adrenaline secretion. Secretion of adrenaline is controlled by presympathetic neurons in the rostroventrolateral medulla which are, in turn, under the control of central and/or peripheral glucose-sensing neurons. Adrenaline is particularly important for counterregulation in individuals with Type 1 (insulin-dependent) diabetes since these patients do not produce endogenous insulin and also lose their ability to secrete glucagon soon after diagnosis. Type 1 diabetic patients are therefore critically dependent on adrenaline for restoration of normoglycaemia and attenuation or loss of this response in hypoglycaemia unawareness can have serious, sometimes fatal, consequences. Understanding neural control of hypoglycaemia-induced adrenaline secretion is likely to identify new therapeutic targets for treating this potentially life-threatening condition.
URI: http://ahro.austin.org.au/austinjspui/handle/1/13744
DOI: 10.1111/bph.13458
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26896587
Type: Journal Article
Subjects: Epinephrine
Hypoglycemia
Diabetes Mellitus
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.